What’s Inside Johnson & Johnson (JNJ)’s Pharmaceuticals Business? – Medivation Inc (MDVN), Merck & Co., Inc. (MRK)

When it comes to health care companies, there’s no bigger name than the largest firm in the business: Johnson & Johnson (NYSE:JNJ).

What doesn’t Johnson & Johnson (NYSE:JNJ) produce? From pharmaceuticals to consumer care goods to medical devices, this major medical player has it all. That can make it tough on investors trying to understand this highly diversified company, however: With so many parts, what do you need to keep an eye on? To get a grip on this colossus of the health care sector, let’s take a look at Johnson & Johnson (NYSE:JNJ) and the company’s top pharmaceuticals powering its revenues today.

Johnson & Johnson (NYSE:JNJ)Rising to the top
Anything related to Johnson & Johnson (NYSE:JNJ)’s pharmaceuticals has to start with Remicade. The anti-inflammatory biologic is the engine to this company’s drug sales, pulling down more than $6 billion in 2012 alone at year-over-year growth of nearly 12%. This drug has crushed expectations and keeps on rising.

Merck & Co., Inc. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ)’s partner on Remicade, turned over the marketing rights to the drug in certain geographic areas back in 2011, fueling Johnson & Johnson (NYSE:JNJ)’s share of the revenue. Remicade doesn’t face a patent expiration until 2018 in the U.S. and 2014 in Europe and Japan; its status as a biologic, rather than a chemical compound, should also impede generic drugmakers from stepping in to launch competition too quickly. Remicade might not be able to keep this level of growth up with such high sales, but it’s a safe bet to keep powering the foundation of Johnson & Johnson (NYSE:JNJ)’s pharmaceutical revenue for the next few years.

Johnson & Johnson (NYSE:JNJ)’s pharmaceuticals are more than just Remicade however, even if the drug takes the spotlight today. Fellow immunology drug Stelara has put on a show worthy of any growth investor’s attention recently as sales swelled nearly 39% in 2012 to exceed the $1 billion mark. This drug, used to treat severe plaque psoriasis, was estimated early last year to hit peak sales of more than $1.5 billion by 2016, but its surge could send sales far over that mark.

Stelara has also shown effectiveness in combating symptoms of Crohn’s disease in clinical trials. While the drug’s still being evaluated as a treatment option, if Stelara is ever approved to fight Crohn’s — an inflammatory bowel disease afflicting more  than 1 million people — J&J could see the drug’s sales soar.

Some of J&J’s former blockbuster heavyweights are on the way down due to generic competition, such as neurology drugs Concerta and Risperdal. However, new blockbuster arrivals have risen to take their place. Oncology drugs Velcade and Zytiga both grew significantly last year — the latter by a whopping 319% to $961 million. Zytiga has picked up expanded approval as a pre-chemo prostate cancer drug from the FDA recently, and peak sales could hit up to $1.8 billion. While Zytiga’s facing tough competition – Medivation Inc. (NASDAQ:MDVN)‘s own prostate cancer drug and rival Xtandi is predicted to reach peak sales of up to $2.2 billion — the drug still should help J&J stay on track.

Leading the sales of today
With Remicade as its foundation, Johnson & Johnson (NYSE:JNJ)’s pharmaceuticals business is in good hands in the near future. Promising growth stories like Stelara and Zytiga offer blockbuster power in coming years, and with a pipeline full of tomorrow’s cash cows, J&J’s drugs are on the right track.

The article What’s Inside Johnson & Johnson’s Pharmaceuticals Business? originally appeared on Fool.com.

Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

6 Ways to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

The Most Heartwarming and Inspirational Story Of This Halloween Season, It Will Make You Cry and Jump For Joy

10 Best Party Songs of All Time to Bring the House Down With

5 New World Order Conspiracy Theories that Will Strangle the World

The 10 Highest Rated Movies of 2014

The 10 Largest Container Shipping Companies in the World

The 10 Largest Armies in the World: Who Should We Be Afraid Of?

Best Warren Buffett Quotes on Money You Need to Hear

The 10 Highest Suicide Rates by Profession

The 20 Most Underrated Movies of All Time

The 10 Fastest Growing Companies in America

The 10 Biggest Outlet Malls in USA

The 5 Most Popular Rap Songs of All Time

The 10 Countries that Eat the Most Meat

The10 Most Expensive Countries to Fly To

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!